Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The investigators hypothesized that local radiation therapy can enhance the effect of
anti-PD-L1 monoclonal antibody through priming T-cell effector function against cancer cells.
Described as above, The investigators concluded that modest dose of radiation to local site
prior to immunotherapy is the best to enhance T-cell-mediated immunity. Accordingly, The
investigators will investigate the combining effect of hypofractionated-sublethal dose of
radiation therapy followed by anti-PD-L1 monoclonal antibody, atezolizumab, for SCLC patients
who are recurrent or refractory for initial platinum-based chemotherapy